GRDX
Entero Therapeutics, Inc.
NASDAQ: GRDX · HEALTHCARE · BIOTECHNOLOGY
$2.51
+17.29% today
Updated 2026-04-30
Market cap
$7.56M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-11.66
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Entero Therapeutics, Inc. (GRDX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $993.00 | $6.58M | $6.69M | $6.75M | $6.55M | $7.47M | $8.90M | $12.92M | $11.79M | $5.44M | $6.88M | $85.41M |
| Cash & equivalents | $48.00 | $94836.00 | $581668.00 | $1.77M | $573471.00 | $1.11M | $175796.00 | $6.06M | $8.25M | $1.36M | $3.71M | $163476.00 |
| Current assets | $933.00 | $663454.00 | $2.07M | $2.96M | $1.95M | $4.80M | $3.41M | $7.87M | $9.42M | $3.41M | $4.96M | $83.48M |
| Total liabilities | $939304.00 | $3.93M | $10.32M | $3.54M | $3.82M | $3.00M | $4.29M | $15.56M | $19.61M | $2.70M | $3.28M | $27.61M |
| Current liabilities | $736.00 | $2.43M | $8.82M | $2.34M | $2.48M | $3.00M | $4.29M | $15.55M | $12.30M | $2.48M | $3.13M | $27.55M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $54598.00 | $2.64M | $-3.63M | $3.21M | $2.73M | $4.47M | $4.62M | $-2.64M | $-7.82M | $2.74M | $3.60M | $57.80M |
| Retained earnings | $-1.01M | $-2.37M | $-8.30M | $-22.89M | $-33.98M | $-47.52M | $-62.69M | $-95.37M | $-153.90M | $-168.53M | $-184.33M | $-202.39M |
| Accounts receivable | — | $428752.00 | $1.07M | $961038.00 | $298474.00 | $3.17M | $2.64M | $551489.00 | — | $93014.00 | — | — |
| Inventory | — | — | — | — | — | — | — | $1.25M | — | $1.95M | — | — |
| Goodwill | — | $2042.00 | $1832.00 | $1767.00 | $2016.00 | $1924.00 | $1886.00 | $2.05M | $1.91M | $1.68M | $1.68M | $1.68M |